Product nameAnti-TLR3 antibody [40C1285.6] (Phycoerythrin)
See all TLR3 primary antibodies
DescriptionMouse monoclonal [40C1285.6] to TLR3 (Phycoerythrin)
ConjugationPhycoerythrin. Ex: 488nm, Em: 575nm
Tested applicationsSuitable for: WB, Flow Cytmore details
Species reactivityReacts with: Human
This antibody was developed against KLH-conjugated synthetic peptide of human TLR3.
- Human intestine or Ramos.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.02% Sodium azide
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab45093 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at a concentration of 1 - 3 µg/ml. Predicted molecular weight: 104 kDa.
This antibody has tested negative by western blot in mouse intestine cell lysate.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionKey component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific of microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
Tissue specificityExpressed at high level in placenta and pancreas. Also detected in CD11c+ immature dendritic cells. Only expressed in dendritic cells and not in other leukocytes, including monocyte precursors. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons.
Involvement in diseaseDefects in TLR3 are associated with herpes simplex encephalitis type 2 (HSE2) [MIM:613002]. HSE is a rare complication of human herpesvirus 1 (HHV-1) infection, occurring in only a small minority of HHV-1 infected individuals. HSE is characterized by hemorrhagic necrosis of parts of the temporal and frontal lobes. Onset is over several days and involves fever, headache, seizures, stupor, and often coma, frequently with a fatal outcome. Note=TLR3 mutations predispose otherwise healthy individuals to isolated herpes simplex encephalitis through a mechanism that involves impaired IFNs production and reduced immune defense against viral infection in the central nervous system.
Sequence similaritiesBelongs to the Toll-like receptor family.
Contains 22 LRR (leucine-rich) repeats.
Contains 1 LRRCT domain.
Contains 1 LRRNT domain.
Contains 1 TIR domain.
Domainds-RNA binding is mediated by LRR 1 to 3, and LRR 17 to 18.
modificationsHeavily N-glycosylated, except on that part of the surface of the ectodomain that is involved in ligand binding.
Cellular localizationEndoplasmic reticulum membrane. Endosome membrane.
- Information by UniProt
- CD283 antibody
- CD283 antigen antibody
- IIAE2 antibody
All lanes : Anti-TLR3 antibody [40C1285.6] (Phycoerythrin) (ab45093) at 1 µg/ml
Lane 1 : A459 cell lysate
Lane 2 : Human skin tissue lysate
Lane 3 : Human lung tissue lysate
Lane 4 : Human dendritic cell lysate
Lane 5 : Human macrophage cell lysate
Lysates/proteins at 15 µg per lane.
All lanes : HRP-conjugated Goat anti-mouse IgG at 1/2000 dilution
Performed under reducing conditions.
Predicted band size: 104 kDa
Observed band size: 104 kDa
Exposure time: 10 minutes
ab45093 staining TLR3 in Human A549 (lung epithelial) cell line by Flow Cytometry. The sample was incubated with the primary antibody (5μg/ml in 0.1% Saponin + 1% FCS in PBS) for 45 minutes at 4°C. 1 = isotype control, 2 = ab45093
ab45093, at 3 ug/ 1X10^6 cells, staining Ramos cells by Intracellular flow cytometric analysis. Toll-Like-Receptor3 (open peak) and isotype negative control (shaded peak).